<-- Return Home

Micro Lab #3 - The impact of intra- and inter-tumoral and patient heterogeneity in the response to combination therapy

Date/Time: September 28, 2021, from 11AM to 2PM EST.

Cancer is dominated by molecular instability that leads to generations of complex cell (sub)populations with different characteristics that perturb the organ functionality and thus the tissue organization and architecture. The variability in the molecular profiles, the cell (sub)populations, the interplay between the cell (sub)populations, and their interaction with the micro-environment leads to unique phenotypes and generates intra- and inter-tumor heterogeneity. This process is dynamic increasing, even more, the complexity of understanding the tumor’s biological state, its cause and progression, which plays a critical role in predicting response in cancer treatment. Furthermore, in clinical practice, the heterogeneity of patient populations plays a role in the ultimate efficacy of the combination. In this Micro Lab we will focus on the role of tumor heterogeneity in cancer combination therapy response and pose several related questions, including but not limited to:

  • What are the relevant types of heterogeneity?

  • How does heterogeneity across scales, cell plasticity, cell to cell, and patient to patient variability affect response to drug combinations?

  • What mechanisms do we have for measuring heterogeneity in the clinic?

  • Exploring intelligent drug delivery systems (spatial treatment of tumors vs systemic)


Clinical Perspective

Boston University

Cancer Biology Perspective


Cancer Biology Perspective


Computational Modeling Perspective

Dana Farber

Apply now >>

<-- Return Home